HDAC6 and neoplasm: These results highlight a previously unrecognized regulatory interaction between metabolic and epigenetic pathways that influence complement signaling, offering new insight into how modulating KYNU and HDAC6 may reshape the tumor immune environment and improve therapeutic responses.